{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:28Z","timestamp":1790622988338,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Project of Scientific and Technological Support Plan of Health Commission of Henan Province","award":["201602210"],"award-info":[{"award-number":["201602210"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Coronary artery disease (CAD) and atrial fibrillation (AF) frequently coexist in clinical practice, making it challenging for the treating physician to choose anticoagulation and antiplatelet therapies. The aim of this study was to investigate antithrombotic strategies and assess related adverse outcomes in stable coronary artery disease (SCAD) and acute coronary syndrome (ACS) patients with AF when the CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score was \u22652.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a retrospective study and collected data from a computer-based patient record management system in Zhengzhou University People\u2019s Hospital in China. In total, 2978 patients with a hospital discharge diagnosis of CAD and concomitant AF who met the inclusion criteria were enrolled from January 1, 2012 to December 31, 2016, and data from 2050 patients were finally analysed. The \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test was used to compare the incidences of clinical endpoints between the SCAD+AF group and the ACS\u2009+\u2009AF group. Multivariable Cox regression analysis was performed to identify independent predictive factors of adverse outcomes in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Oral anticoagulant (OAC) monotherapy was the most common antithrombotic therapy in SCAD+AF patients (49.55%), while double antiplatelet therapy (DAPT) was the most common treatment in ACS\u2009+\u2009AF patients (54.19%) at discharge. OAC monotherapy significantly increased and the use of single antiplatelet therapy (SAPT) decreased during follow-up (34\u2009\u00b1\u200913\u2009months) when compared to their use at discharge in the SCAD+AF group (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In the ACS\u2009+\u2009AF group, the proportion of patients using DAPT decreased notably, while the proportions of patients using SAPT and dual therapy (DT) combining OAC with SAPT increased significantly during follow-up (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to the proportions at discharge. According to multivariable Cox regression analysis, age, hypertension and prior stroke were independent risk factors for ischaemic stroke in the SCAD+AF group and ACS\u2009+\u2009AF group (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). OAC was an independent protective factor for ischaemic stroke in both groups (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Previous bleeding independently increased the risk of haemorrhage in both groups (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, the proportion of anticoagulant-antiplatelet combined therapy was low in ACS\u2009+\u2009AF patients with high stroke risk. In clinical practice, the awareness of anticoagulation needs to be strengthened regarding patients with CAD and AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-020-01609-8","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T08:03:44Z","timestamp":1594022624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antithrombotic therapy in coronary artery disease patients with atrial fibrillation"],"prefix":"10.1186","volume":"20","author":[{"given":"Lili","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Datun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-3105","authenticated-orcid":false,"given":"Chuanyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"1609_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ahj.2016.08.008","volume":"181","author":"RC Welsh","year":"2016","unstructured":"Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J. 2016;181:92\u2013100.","journal-title":"Am Heart J"},{"issue":"23","key":"1609_CR2","first-page":"e199","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199\u2013267.","journal-title":"Circulation"},{"issue":"38","key":"1609_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"7","key":"1609_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.hrthm.2013.03.017","volume":"10","author":"HF Tse","year":"2013","unstructured":"Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm. 2013;10(7):1082\u20138.","journal-title":"Heart Rhythm"},{"issue":"14","key":"1609_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","volume":"64","author":"M Hamon","year":"2014","unstructured":"Hamon M, Lemesle G, Tricot O, Meurice T, Deneve M, Dujardin X, Brufau JM, Bera J, Lamblin N, Bauters C. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1609_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","volume":"129","author":"M Lamberts","year":"2014","unstructured":"Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sorensen R, Kober L, Torp-Pedersen C, Hansen ML. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129(15):1577\u201385.","journal-title":"Circulation"},{"issue":"2","key":"1609_CR7","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"3","key":"1609_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360.","journal-title":"Eur Heart J"},{"issue":"16","key":"1609_CR9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"7","key":"1609_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1160\/TH16-11-0876","volume":"117","author":"G Lip","year":"2017","unstructured":"Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230\u20139.","journal-title":"Thromb Haemost"},{"issue":"9872","key":"1609_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107\u201315.","journal-title":"Lancet"},{"issue":"10","key":"1609_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"Investigators G","year":"1993","unstructured":"Investigators G. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673\u201382.","journal-title":"N Engl J Med"},{"issue":"19","key":"1609_CR13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1161\/CIR.0000000000000095","volume":"130","author":"SD Fihn","year":"2014","unstructured":"Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, et al. 2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749\u201367.","journal-title":"Circulation"},{"issue":"11","key":"1609_CR14","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1161\/STROKEAHA.112.670893","volume":"43","author":"D Wang","year":"2012","unstructured":"Wang D, Liu M, Hao Z, Tao W, Lin S, Zhang S, Wu B, Ma Z, Dong W. Features of acute ischemic stroke with rheumatic heart disease in a hospitalized Chinese population. Stroke. 2012;43(11):2853\u20137.","journal-title":"Stroke"},{"issue":"7329","key":"1609_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"C Antithrombotic Trialists","year":"2002","unstructured":"Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"issue":"1","key":"1609_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40360-017-0189-7","volume":"18","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Shi JX, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacol Toxicol. 2017;18(1):80.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"1609_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCULATIONAHA.118.037440","volume":"139","author":"G Lemesle","year":"2019","unstructured":"Lemesle G. Aspirin on top of anticoagulation in patients with concomitant stable coronary artery disease and atrial fibrillation. Circulation. 2019;139(5):617\u20139.","journal-title":"Circulation"},{"issue":"10","key":"1609_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","volume":"126","author":"M Lamberts","year":"2012","unstructured":"Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185\u201393.","journal-title":"Circulation"},{"issue":"5","key":"1609_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127(5):634\u201340.","journal-title":"Circulation"},{"key":"1609_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","volume":"179","author":"R Shah","year":"2016","unstructured":"Shah R, Hellkamp A, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Fox KA, et al. Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial. Am Heart J. 2016;179:77\u201386.","journal-title":"Am Heart J"},{"issue":"10","key":"1609_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/clc.22750","volume":"40","author":"G Lemesle","year":"2017","unstructured":"Lemesle G, Ducrocq G, Elbez Y, Van Belle E, Goto S, Cannon CP, Bauters C, Bhatt DL, Steg PG, Investigators R. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events. Clin Cardiol. 2017;40(10):932\u20139.","journal-title":"Clin Cardiol"},{"issue":"1","key":"1609_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/2048872615610868","volume":"6","author":"PG Steg","year":"2017","unstructured":"Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2017;6(1):93\u20137.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"5","key":"1609_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","volume":"138","author":"DJ Angiolillo","year":"2018","unstructured":"Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, et al. Antithrombotic therapy in patients with atrial fibrillation treated with Oral anticoagulation undergoing percutaneous coronary intervention: a north American Perspective-2018 update. Circulation. 2018;138(5):527\u201336.","journal-title":"Circulation"},{"issue":"2","key":"1609_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"50","key":"1609_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005581","volume":"95","author":"N Chaudhary","year":"2016","unstructured":"Chaudhary N, Bundhun PK, Yan H. Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95(50):e5581.","journal-title":"Medicine (Baltimore)"},{"issue":"9921","key":"1609_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"25","key":"1609_CR27","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334.","journal-title":"N Engl J Med"},{"issue":"16","key":"1609_CR28","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, et al. Dual Antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513\u201324.","journal-title":"N Engl J Med"},{"issue":"1","key":"1609_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12872-016-0343-y","volume":"16","author":"PK Bundhun","year":"2016","unstructured":"Bundhun PK, Yanamala CM, Huang F. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord. 2016;16(1):161.","journal-title":"BMC Cardiovasc Disord"},{"key":"1609_CR30","doi-asserted-by":"publisher","first-page":"7372129","DOI":"10.1155\/2019\/7372129","volume":"2019","author":"Y Sun","year":"2019","unstructured":"Sun Y, Zhu J, Ma C, Liu S, Yang Y, Hu D. Stroke risk status, anticoagulation treatment, and quality-of-life in Chinese patients with atrial fibrillation: China registry of atrial fibrillation (CRAF). Cardiovasc Ther. 2019;2019:7372129.","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"1609_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1609_CR32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","volume":"42","author":"EF Lewis","year":"2003","unstructured":"Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA, Study C. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42(8):1446\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1609_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/eurheartj\/ehn062","volume":"29","author":"EF Lewis","year":"2008","unstructured":"Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and\/or left ventricular dysfunction: a VALIANT study. Eur Heart J. 2008;29(6):748\u201356.","journal-title":"Eur Heart J"},{"issue":"1","key":"1609_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12872-017-0511-8","volume":"17","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Chaudhary N, Yuan J. Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):83.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1609_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12872-016-0449-2","volume":"17","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Soogund MZ, Teeluck AR, Pursun M, Bhurtu A, Huang WQ. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017;17(1):15.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01609-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01609-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T19:28:48Z","timestamp":1625513328000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01609-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1609"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01609-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was approved by the Ethics Committee of Zhengzhou University People\u2019s Hospital [NO.2016(40)] and was exempted from the requirement for informed consent. All information used for data analysis in this study was anonymized.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}